App Profile: COAPT Risk Score

For educational purposes and for use by medical professionals only. For patients with severe functional mitral regurgitation and symptomatic heart failure (left ventricular ejection fraction between 20-50%) despite best medical therapy.

The COAPT Risk Score is a simple risk prediction tool created by combining clinical and echocardiographic variables in patients with heart failure (HF) and moderate-to-severe or severe functional mitral regurgitation (FMR) who remain symptomatic despite maximally tolerated guideline directed medical therapy (GDMT). The COAPT Risk Score provides valuable prognostic information regarding the 2-year risk of death and/or heart failure hospitalization (HFH). The score is derived from the COAPT trial population of patients with HF and moderate-to-severe or severe FMR randomized to treatment with either transcatheter edge-to-edge repair (TEER) with MitraClip plus GDMT or GDMT alone. We can incorporate TEER in the risk score and provide updated 2-year risk of death and/or HFH which can serve as a valuable shared decision-making tool for patients and physicians as well as heart teams while deciding about TEER.

Created by a team of subject-matter experts including: the director of The Mount Sinai Hospital cardiac cath lab Dr. Kini, Director of Clinical and Interventional Cardiology at the Mount Sinai Health System Dr Sharma, the Mount Sinai Hospital Surgical Director Dr. Tang, COAPT Principal Investigator Dr. Stone, and COAPT Risk Score publication author Dr. Shah.